Von Eschenbach still in limbo
Senate Finance Committee Chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach to be permanent FDA commissioner Nov. 16. The senator objects to von Eschenbach's "failure to comply with the committee's subpoenas over the past six months." In May, Grassley requested a briefing by senior FDA staff, a meeting with a line investigator and access to study data related to Sanofi-Aventis' Ketek (telithromycin) after allegations of data integrity problems in the antibiotic's NDA. Grassley is the third Senator to place a hold on the nomination, following Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.). Senate Health Committee Chair Mike Enzi (R-Wyo.) has vowed to work to lift the holds to allow for confirmation before Congress adjourns (1"The Pink Sheet" Sept. 25, 2006, p. 4)...
You may also be interested in...
Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.